Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

PURPOSE CD19-targeted chimeric antigen receptor T cells (CD19-CAR) and blinatumomab
effectively induce remission in relapsed or refractory B-cell acute lymphoblastic leukemia …

Leukemia, most commonly B-cell acute lymphoblastic leukemia (B-ALL), accounts for about
30% of childhood cancer diagnoses. While there have been dramatic improvements in …

Downregulation of surface epitopes causes postimmunotherapy relapses in B-lymphoblastic
leukemia (B-ALL). Here we demonstrate that mRNA encoding CD22 undergoes aberrant …

Background Boys with acute lymphoblastic leukemia (ALL) have historically experienced
inferior survival compared to girls. This study determined whether sex‐based disparities …

ABSTRACT HLA-haploidentical transplantation (haplo-HCT) using post-transplantation-
cyclophosphamide (PT-Cy) is a feasible procedure in children with malignancies. However …

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the
uncontrolled proliferation of immature lymphoid cells. Over past decades, significant …

PURPOSE Patients with Down syndrome (DS) and B-ALL experience increased rates of
relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on …

Acute lymphoblastic leukemia (ALL) is a malignancy with high heterogeneity in its biological
features and treatments. Although the overall survival (OS) of patients with ALL has recently …

The clinical development of antibody–drug conjugates (ADCs) has gained momentum in
recent years and these agents are gradually moving into frontline regimens for pediatric …